AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amphastar Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$26.14+0.27 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Amphastar Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical products segment | $719.89M | $731.97M | $644.40M | $498.99M | – | – | – | – | – | – | 100.0% | -1.7% |
| Finished Pharmaceutical Products Segment | – | – | $630.27M | $486.51M | $419.57M | $331.37M | $302.00M | $271.06M | $230.14M | $240.22M | – | – |
| Active Pharmaceutical Ingredient Segment | – | – | $14.12M | $12.48M | $18.20M | $18.48M | $20.36M | $23.61M | $10.04M | $14.94M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $719.89M | $712.81M | $593.24M | $498.99M | $437.77M | – | – | – | – | – | 100.0% | +1.0% |
| Other | – | $19.15M | $51.16M | – | – | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $681.42M | $707.68M | $635.19M | $486.83M | $419.87M | $333.09M | $304.90M | $279.12M | $234.32M | $249.01M | 94.7% | -3.7% |
| France | $35.28M | $19.95M | $4.70M | $7.46M | $11.88M | $13.59M | $15.98M | $15.54M | $5.85M | $6.16M | 4.9% | +76.9% |
| China | $3.18M | $4.34M | $4.51M | $4.70M | $6.02M | $3.16M | $1.48M | – | – | – | 0.4% | -26.6% |
From the segment and revenue-disaggregation notes of Amphastar Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.